Anzalone Christopher Richard

CEO Anzalone sells 13,187 shares at $66.10 avg for $871.7K; 5th consecutive sale in 7 days

Christopher Richard Anzalone, Chief Executive Officer, executed 2 separate sales totaling 13,187 shares for $871,702.77, reducing holdings from 3.81M to 3.79M shares (-0.3%). This sale follows 4 prior sales at ARWR within the previous 7 calendar days (2025-12-19, 2025-12-22, 2025-12-29), establishing a concentrated selling pattern. The transaction prices of $65.88 and $66.39 on 2026-01-02 sit 3.2% below the current price of $63.88, though remain well above the 52-week low of $9.99 and near the upper half of the 52-week range. The company's fundamentals show significant distress: the most recent full fiscal year reported net income of $-175.2M against quarterly revenue of $27.8M, placing the firm in unprofitable territory despite 90-day stock momentum of +74.8%. Taken together, the CEO's repeated sales in consecutive trading windows warrant close monitoring of institutional and advisory positioning, particularly given the contradiction between recent positive price momentum and the company's sustained operating losses.

ARWR CEO Anzalone sells 51,726 shares in 2 transactions for $3,575,574.78; holds 3.81M shares post-sale

Christopher Richard Anzalone, CEO of Arrowhead Pharmaceuticals, executed 2 separate sales on 2025-12-29, offloading 51,726 shares (51.7K shares) for $3,575,574.78 at a blended average price of $69.13. His post-transaction holdings of 3.81M shares represent a -1.3% reduction from prior holdings of 3.86M shares. The sale occurs in a stock trading near its 52-week high of $70.82 and is the latest in a recent series of five ARWR sales executed across 2025-12-19 through 2025-12-22. Notably, the company reported a $-175.2M net loss in its latest quarter despite $27.8M in revenue and remains unprofitable on a full-year basis, though it shows exceptional annual revenue growth of +23258.2%. This sale warrants scrutiny given the frequency of recent transactions and the company's negative profitability backdrop.

ARWR CEO Anzalone sells 26,031 shares for $1,771,022.38 across 5 transactions Dec 19-22

Christopher Richard Anzalone, Chief Executive Officer of Arrowhead Pharmaceuticals, executed 5 separate sales totaling 26,031 shares for $1,771,022.38 between December 19 and December 22, 2025, at a blended average price of $68.04. The stock has since appreciated to $69.83 (current price), representing a modest unrealized gain on the executed sales. His post-transaction holdings of 3,805,926 shares represent a 0.7% reduction in his position. The stock has appreciated 72.6% over the prior 30 days and 112.7% over the prior 90 days, positioning these sales near the 52-week high ($70.82). His cross-ticker track record shows 20 prior open-market sells with a 0.00% well-timed rate at the 90-day mark, indicating his prior sales have not positioned him ahead of subsequent price declines. At the company level, Arrowhead is unprofitable (net income of $-175,241,000.00 for the most recent full fiscal year) despite strong revenue growth of 23258.2% year-over-year, with a quarterly revenue of $27,767,000.00 and market cap of $9,483,581,435.14.

ARWR CEO Anzalone sold 85,000 shares for $5.4M on 2025-12-17 at $64.04 blended price; retains 3.83M shares.

Christopher Richard Anzalone, Chief Executive Officer of Arrowhead Pharmaceuticals, executed 4 separate sales totaling 85,000 shares for $5,443,462.11 on 2025-12-17, with transaction prices ranging from $63.55 to $66.30 and a blended average price of $64.04. Post-transaction holdings of 3,831,957 shares represent a 2.2% reduction from pre-transaction levels, leaving the CEO with substantial continued ownership. The timing of these sales is notable given the stock's recent performance: the current price of $68.16 sits 3.8% below the 52-week high of $70.82, but the stock has surged 74.9% over the past 30 days and 122.1% over the past 90 days. The company's fundamentals present a mixed picture—revenue grew 23258.2% year-over-year driven by acquisitions and strategic shifts, but the business remains unprofitable with a net loss of $175,241,000.00 in the latest quarter and full-year negative net income. Across all his open-market history, Anzalone's cross-ticker track record shows 20 prior sells with an average 90-day return of +65.4% following those sales, indicating those sells were poorly timed (the stock rose after he sold), with a 0.00% well-timed rate. This pattern of selling into strength, combined with the company's ongoing unprofitability despite revenue expansion, merits investor attention.

ARWR CEO Anzalone sells 184,298 shares for $12,348,801.97 across 12 transactions; holds 3.92M shares post-sale

Christopher Richard Anzalone, Chief Executive Officer of Arrowhead Pharmaceuticals, executed 12 separate sales totaling 184,298 shares for $12,348,801.97 between December 15–16, 2025, reducing his holdings by 4.5% to 3.92M shares. The sales occurred at prices ranging from $60.51 to $69.96, with a blended average of $67.00, near the 52-week high of $70.82 and well above current price of $64.66. Notably, across his 5 prior trades at ARWR, Anzalone's sells have consistently been poorly timed: all 5 were followed by positive 90-day returns (ranging from +49.2% to +76.6%), meaning the stock rose after each sale. This established pattern stands in sharp contrast to the data: a CEO selling material value at elevated prices after a 56.7% 30-day and 122.0% 90-day surge warrants attention, particularly given the company's unprofitable operations (net income $-175.2M) despite strong recent stock momentum. The sustained underperformance of his ARWR timing signals merit review of whether this represents risk management in a volatile position or market dynamics independent of fundamental valuation.

CEO Anzalone sold 141,122 shares (3.5% of holdings) for $1,533,336.57 across 5 sales at ARWR in April 2025 as stock fell 25.2% in 30 days, 36.2% in 90 days from $29.54 peak.

Anzalone sold 141,122 shares (141.1K shares) totaling $1,533,336.57 at blended average price $10.87 across five separate sales on April 9–11, 2025. The timing context is material: ARWR is trading at $11.79, down 60.1% from its 52-week high of $29.54, with a 30-day decline of 25.2% and 90-day decline of 36.2%, signaling severe recent momentum loss. His prior five trades at this ticker show 2 of 2 measurable 90-day outcomes were negative returns (-26.4% and -31.8%), indicating a pattern of selling before multi-month declines. The company fundamentals are severely stressed: revenue contracted 98.5% year-over-year (latest quarter revenue $2,500,000.00), net income was -$173,085,000.00, and the company remains unprofitable on a full-year basis. Although Anzalone retains 3,921,255 shares (3.92M shares) post-transaction, the sale size, stock price weakness, and his historical ability to sell ahead of extended declines warrant investor scrutiny of forward-looking guidance and operational headwinds.

ARWR CEO Anzalone sells 51,425 shares at $15.07 on 2025-03-13; stock -47.2% from 52-week high, -30.0% over 90 days.

Christopher Richard Anzalone, Chief Executive Officer of Arrowhead Pharmaceuticals, sold 51,425 shares (reducing holdings from 4,113,802 to 4,062,377 shares) at $15.07 on 2025-03-13 for $774,974.75. The timing context is concerning: the stock has declined -47.2% from its 52-week high of $29.54 and is down -30.0% over the prior 90 days. His cross-ticker track record shows a 62.50% well-timed rate across 13 prior sells, but at ARWR specifically, his prior five transactions (all sells in late February and December 2024) show a -4.7%, -11.6%, and -10.0% 30-day outcomes, with none yet measurable at the 90-day threshold. The company's fundamentals deteriorated sharply: annual revenue growth is -98.5%, net income was negative at -$173.1M for the latest full fiscal year, and most recent quarterly revenue stands at only $2.5M. The CEO's sale during this period of sharp price erosion and severe operational contraction merits close investor attention.

CEO Anzalone sells 300,000 ARWR shares for $5.3M as stock falls 22.2% in 90 days; unprofitable company reports -98.5% annual revenue decline

Christopher Richard Anzalone, CEO of Arrowhead Pharmaceuticals, executed 2 separate sales totaling 300,000 shares (300.0K shares) for $5,274,333.67 ($5.3M) on March 3–4, 2025, reducing his holdings by 7.4%. The stock has declined 22.2% over the prior 90 days and trades 51.9% below its 52-week high of $36.08, currently at $17.35—below the blended sale price of $17.58. At the same ticker, his prior 2 measurable 90-day sales outcomes were well-timed, as the stock fell -29.7% and -30.8% after those trades. Fundamentals show severe deterioration: annual revenue collapsed -98.5% to $2.5M in the latest quarter, and the company posted a $-173.1M net loss over its most recent full fiscal year. The combination of sustained stock weakness, poor fundamentals, and his historical pattern of well-timed sells at this ticker suggests the sales occurred within a context of deteriorating business performance rather than opportunistic liquidation at peak valuations.

CEO Anzalone sold 26,712 shares across 3 transactions at $20.52–$22.12 for $567,485.84; stock now at $19.45.

CEO Christopher Richard Anzalone executed 3 separate sales totaling 26,712 (26.7K shares) for $567,485.84 on 2024-12-18, with a blended average price of $21.24—a 9.2% premium to the current price of $19.45. Despite the large sale, his post-transaction holdings of 3,788,335 shares (3.79M shares) represent a minimal -0.7% reduction from prior holdings, suggesting this was a discrete divestment rather than a systematic position liquidation. His prior trades at ARWR show mixed timing outcomes: 2 of 5 prior sells at this ticker were well-timed at the 90-day mark, yet his cross-ticker track record across 8 prior sells exhibits a 90d well-timed rate of 62.50% with an average 90d return of -7.9%, indicating a history of selling into weakness. The company's fundamentals are severely distressed—latest quarter revenue is $0.00, full-year net income was -$170,793,000.00, and annual revenue growth declined -98.5%—creating a context where near-term insider liquidity decisions warrant investor scrutiny, though the data cannot definitively characterize the trade's forward-looking intent.